Defining asthma phenotypes: Focusing the picture - 07/08/11

Key words : Asthma, asthma control, asthma impairment, asthma risk, asthma severity, biomarkers, genetics, inhaled corticosteroids, leukotriene receptor antagonists, long-acting ß-adrenergic agonists
Le texte complet de cet article est disponible en PDF.
Plan
| Supported in part by Public Health Services research grants HR 16048, HL 64288, HL 51834, AI 25496, HL 081335, and HL 075416; the Colorado Cancer, Cardiovascular and Pulmonary Disease Program; and Colorado CTSA grant 1 UL1 RR025780 from the National Institutes of Health and the National Center for Research Resources. |
|
| Disclosure of potential conflict of interest: S. J. Szefler is a consultant for GlaxoSmith-Kline, Genentech, Merck, Boehringer-Ingelheim, Novartis, and Schering-Plough and has received research support from the National Institutes of Health (NIH)/NHLBI Childhood Management Program, NHLBI Childhood Asthma Research and Education, the NIH/NHLBI Asthma Clinical Research Network, the NIH/NIAID Inner City Asthma Consortium, GlaxoSmithKline, NIH/NHLBI Asthma Net, and the NIEHS/EPA Childhood Environmental Health Center. |
Vol 126 - N° 5
P. 939-940 - novembre 2010 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
